Medical/Pharmaceuticals
Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
HIGHLIGHTS
* Oral presentation on key results from the Co-PSMA (NCT06907641
Metabolon Collaborates with The Michael J. Fox Foundation to Advance Multiomic Analyses for Parkinson's Research
Partnership supports expanded biomarker discovery efforts within MJFF's
Parkinson's Progression Markers Initiative
MORRISVILLE, N.C., March 17, 2026 /PRNewswire/ -- Metabolon
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therap...
Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models
- In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC50 for human amylin 1 receptor (hAMY1R) was 21.4 pM and 21.2 pM for ASC39 and elo...
/C O R R E C T I O N -- Gesynta Pharma/
In the news release, First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat, issued 11-Mar-2026 by Gesynta Pharma over PR Newswire, the source was erroneously mentioned as Getinge Group rather than as Gesynta Pharma as incorrectly transmitted by PR Newswire. The complete, cor...
Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
SUZHOU, China and MÖLNDALS, Sweden, March 17, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleo...
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027
SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) tar...
Dr Cho Li Wei of LW Cho Endocrine Clinic Marks 27 Years of Clinical Practice and Multilingual Care
SINGAPORE, March 17, 2026 /PRNewswire/ -- Dr Cho Li Wei, leading LW Cho Endocrine Clinic, is marking 23 years in endocrinology and 27 years in clinical practice, with a continued focus on bridging language gaps in specialist medical care. The clinic serves patients across conditions including dia...
BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd
Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
SHANGHAI, March 16, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK)optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to accelerate the discovery of n...
Laronix Launches Voice Restoration Study for ICU Patients at Greater Baltimore Medical Center
NEW YORK, March 16, 2026 /PRNewswire/ -- Laronix, Inc., a commercial-stage medical technology (MedTech) company and industry-leading innovator in voice restoration technologies, and the Greater Baltimore Medical Center (GBMC) announced the launch of an investigational study of Laronix MIRA Voice ...
Field Medical Names Mark A. Turco, MD, as Chief Executive Officer
CARDIFF-BY-THE-SEA, Calif., March 16, 2026 /PRNewswire/ -- Field Medical, Inc
Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management
* A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for at least 1 month. The study also confirmed a favorable safety profile with repeated use, par...
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
* AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available inthe United States * The launch of AVTOZMA SC further diversifies Celltrion's immunology portfolio beyond TNF-alp...
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Group Performance * Revenue: US$959.5 million, +61.4% year-on-year * Gross profit: US$553.2 million, +103.3% year-on-year * Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Performance * GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year ...
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call
SHANGHAI, March 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial re...
KLN Named Full-line Distributor for APT Medical's Coronary Intervention Products in Hong Kong
HONG KONG, March 16, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) is pleased to announce that its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), is now the full-line distributor for APT Medical Inc.'s ('APT Medical'; Stock Code 688617.SH) coronary inte...
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (N...
Trial to test mild hyperbaric oxygen therapy during active treatment for aggressive brain cancer
LISMORE, Australia, March 15, 2026 /PRNewswire/ -- Australian researchers from Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG) will launch a clinical study investigating whether hyperbaric oxygen therapy (HBOT) can safely support patients undergoing treatment f...
SUBANG JAYA MEDICAL CENTRE RANKED AMONG THE WORLD'S TOP 250 HOSPITALS AND TOP 10 REGIONALLY IN NEWSWEEK'S 2026 RANKING
KUALA LUMPUR, Malaysia, March 16, 2026 /PRNewswire/ -- Subang Jaya Medical Centre (SJMC) has been named among the Top 250 hospitals globally and top 10 regionally in Newsweek's World's Best Hospitals 2026, placing it among a select group of leading hospitals worldwide. The recognition highlights ...
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 317 media titles]
2026-06-08 10:16Visa Partners with OpenAI to Power the Next Generation of AI Commerce
[Picked up by 304 media titles]
2026-06-11 09:30QuettaFlow Technologies Strengthens Global Strategic Alliance with Lead Wealth and Showcases VasEdge at COMPUTEX Taipei 2026
[Picked up by 294 media titles]
2026-06-11 10:00Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 286 media titles]
2026-06-08 09:00HKC, ANTGAMER, KOORUI Make Strong Debut at COMPUTEX 2026 with World-First Display Innovations
[Picked up by 279 media titles]
2026-06-10 11:13